Intra-cellular Therapies, Inc. (NASDAQ: ITCI) reported Q2 EPS of ($0.15), $0.08 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $319.2 thousand versus the consensus estimate of $410 thousand.

For earnings history and earnings-related data on Intra-cellular Therapies, Inc. (ITCI) click here.